IL294722A - cxcl8 inhibitor and its pharmaceutical composition for use in the treatment of cancer-related fatigue - Google Patents

cxcl8 inhibitor and its pharmaceutical composition for use in the treatment of cancer-related fatigue

Info

Publication number
IL294722A
IL294722A IL294722A IL29472222A IL294722A IL 294722 A IL294722 A IL 294722A IL 294722 A IL294722 A IL 294722A IL 29472222 A IL29472222 A IL 29472222A IL 294722 A IL294722 A IL 294722A
Authority
IL
Israel
Prior art keywords
cxcl8
cancer
inhibitor
treatment
pharmaceutical composition
Prior art date
Application number
IL294722A
Other languages
English (en)
Hebrew (he)
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Publication of IL294722A publication Critical patent/IL294722A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL294722A 2020-02-21 2022-07-12 cxcl8 inhibitor and its pharmaceutical composition for use in the treatment of cancer-related fatigue IL294722A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20158787.0A EP3868369A1 (en) 2020-02-21 2020-02-21 Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
PCT/EP2021/054231 WO2021165510A1 (en) 2020-02-21 2021-02-19 Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue

Publications (1)

Publication Number Publication Date
IL294722A true IL294722A (en) 2022-09-01

Family

ID=69723868

Family Applications (1)

Application Number Title Priority Date Filing Date
IL294722A IL294722A (en) 2020-02-21 2022-07-12 cxcl8 inhibitor and its pharmaceutical composition for use in the treatment of cancer-related fatigue

Country Status (7)

Country Link
US (1) US20230090111A1 (https=)
EP (2) EP3868369A1 (https=)
JP (1) JP2023519491A (https=)
AU (1) AU2021222360A1 (https=)
CA (1) CA3166653A1 (https=)
IL (1) IL294722A (https=)
WO (1) WO2021165510A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
PL1776336T3 (pl) 2004-03-23 2010-06-30 Dompe Farm Spa Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO2021165510A1 (en) 2021-08-26
JP2023519491A (ja) 2023-05-11
AU2021222360A1 (en) 2022-09-01
US20230090111A1 (en) 2023-03-23
CA3166653A1 (en) 2021-08-26
EP4106739A1 (en) 2022-12-28
EP3868369A1 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
IL281999A (en) YAP/TAZ-TEAD interaction inhibitors and their use in cancer therapy
IL283149A (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
IL268327A (en) A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases
ZA202307970B (en) Compounds for use in the treatment and prevention of covid- 19
SG10202002898RA (en) A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease
IL266623A (en) A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer
ES3063421T3 (en) Modified oligonucleotides for use in treatment of tauopathies
IL289758B2 (en) Proportin inhibitors for use in the prevention and treatment of kidney injury
IL290192A (en) Nitanin analogs and their use in the treatment of chronic and acute pain
IL319269A (en) Combination of DCC-3116 and MAPKAP pathway inhibitors for use in cancer treatment
PL3902548T3 (pl) Inhibitor egfr z powodującą oporność na leczenie mutacją l718 i/lub l792 do stosowania w leczeniu nowotworu
IL294722A (en) cxcl8 inhibitor and its pharmaceutical composition for use in the treatment of cancer-related fatigue
EP4193995A4 (en) USE OF BTK INHIBITORS TO TREAT DISEASES
HK40080023A (en) Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
ES3064658T3 (en) Recombinant alpha-a-crystallin and combinations for use in the treatment of cancer
PL3829553T3 (pl) Kompozycja do stosowania do zapobiegania i/lub leczenia śluzówki układu moczowo-płciowego
IL312428A (en) Use of Maribavir for treatment and their treatment methods
PL4346847T3 (pl) Kompleks wielojonowy do stosowania w profilaktyce lub leczeniu zapalenia neurogennego
GB2610895B (en) Composition for use in the treatment and/or prevention of mycotoxic disease
GB202107297D0 (en) Composition for use in the treatment and/or prevention of mycotoxic disease
GB201908110D0 (en) Compositions and methods for use in the treatment of cancer-related fatigue
GB202202541D0 (en) Composition for use in the treatment and/or prevention of mycotoxic disease
PT3589632T (pt) Novos inibidores de glutaminil ciclases bacterianas para utilização no tratamento de doenças periodontais e relacionadas
HK40081983A (en) Cxcl8 inhibitors for use in the treatment of covid-19
IL307475A (en) Oxazepine compounds and their uses in cancer treatment